Liu Ruiqiong, Wei Wei, Hou Huaying, Cong Ping, Zhou Yong, Yu Xiaoming
Cancer Center, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, People's Republic of China.
Onco Targets Ther. 2022 Jul 11;15:771-776. doi: 10.2147/OTT.S362185. eCollection 2022.
Primary spinal cord glioblastoma (PSC GBM) is a rare disease with limited treatment options. Here, we describe a case of PSC GBM treated with anlotinib in this report. Molecular characterization confirmed the presence of the promoter unmethylated, wild type, p.S249C and p53 p.V73fs mutations in the patient. Anlotinib is a multitarget tyrosine kinase inhibitor that target VEGFR2/3, FGFR1-4, PDGFRα/β, and c-kit. After a partial resection of the tumor at the extramedullary invasion site, the patient was administered anlotinib 12 mg p.o. once every day (days 1-14, 21-day cycle) in combination with irinotecan chemotherapy (days 1 and 8, 21-day cycle). The patient exhibited significant symptom remission and partial response and was maintained for more than 10 months of follow-up. This case study showed that S249C may be a new marker for the treatment of PSC GBM with anlotinib. This case is also another strong support for molecular diagnosis and precision medicine.
原发性脊髓胶质母细胞瘤（PSC GBM）是一种治疗选择有限的罕见疾病。在此报告中，我们描述了一例接受安罗替尼治疗的PSC GBM病例。分子特征分析证实该患者存在启动子未甲基化、野生型、p.S249C和p53 p.V73fs突变。安罗替尼是一种多靶点酪氨酸激酶抑制剂，作用于VEGFR2/3、FGFR1 - 4、PDGFRα/β和c-kit。在髓外侵犯部位对肿瘤进行部分切除后，患者口服安罗替尼12 mg，每天一次（第1 - 14天，21天为一个周期），并联合伊立替康化疗（第1天和第8天，21天为一个周期）。患者症状显著缓解且有部分缓解反应，并维持了超过10个月的随访。该病例研究表明，S249C可能是安罗替尼治疗PSC GBM的一个新标志物。该病例也是对分子诊断和精准医学的又一有力支持。
